JobsOhio Growth Capital Fund
VC Fund
Columbus, United States
JobsOhio Growth Capital Fund is a VC fund in Columbus focused on Health Care and Information Technology. JobsOhio Growth Capital (JOGC) program is a syndicate (sidecar) fund that allocates investments to companies who are Ohio-based or planning to locate a significant presence in Ohio as early-stage venture-backed companies.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries JobsOhio Growth Capital Fund invests in
Stages JobsOhio Growth Capital Fund invests in
Countries JobsOhio Growth Capital Fund invests in
Investment Focus
Industry
- Health Care 6 (40%)
- Information Technology 5 (33%)
- Medical 3 (20%)
- Biotechnology 3 (20%)
- Software 2 (13%)
Stage
- Series A 7 (47%)
- Series C 3 (20%)
- Series B 2 (13%)
- Funding Round 2 (13%)
- Seed 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AlensiaXR
|
AlensiaXR, is a technology startup founded by Case Western Reserve University (CWRU) to enhance HoloAnatomy software. | $3.2M / Series A / Feb 01, 2024 | |
Clarametyx Biosciences
|
Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms. | $33M / Series A / Jan 05, 2024 | |
Lentechs
|
Lentechs is a medical device company that develops a novel soft bifocal contact lens. The company is headquartered in Columbus, Ohio. | $6M / Venture - Series Unknown / Oct 24, 2023 | |
Enspire DBS Therapy
|
Enspire DBS Therapy supports stroke recovery patients using deep brain stimulation with physical rehabilitation to restore motor function. Enspire DBS offers a robust method to mediate the effects of stimulation and stroke rehabilitation. | $17.6M / Series B / Aug 01, 2023 | |
Invirsa
|
Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa'stechnology is first being developed in the ophthalmology and pulmonary space.Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone. | $7.7M / Series B / Jun 14, 2023 | |
Mediview XR
|
MediView AR, LLC is a startup Ohio based medical device company that has designed and patented intellectual property in development of Extended Reality Surgical Navigation with intended use in ablation and biopsy of cancerous tumors. | $15M / May 16, 2023 | |
FRAYT
|
FRAYT is a developer of a delivery application offering shipping services. The company enables businesses and retailers to offer same-hour delivery to their customers, from coast to coast. | $7M / Series A / Apr 11, 2023 | |
Biohm Technologies
|
After over 20 years of research supported by the National Institutes of Health (NIH), Dr. Ghannoum’s work on the microbiome has converged into one of the biggest discoveries in digestive health. The discovery is how bad bacteria and bad fungus work together to create digestive plaque. This destructive film protects bad bacteria and bad fungi asthey work to upset the balance of your digestive system. His solution marked the dawning of a new generation of probiotics with dual-action technology that first breaks open digestive plaque, and then neutralizes the bad bacteria and bad fungi, which allows the gut to maintain its natural microbiome balance, ultimately supporting optimal digestive health | $7.5M / Seed / Jan 12, 2023 | |
Genetesis
|
Genetesis is a rapidly growing medical technology company redefining the way patients with a risk of myocardial ischemia and coronary artery disease are clinically diagnosed, monitored and screened. | $17.5M / Series C / Oct 06, 2022 | |
Drive My Way
|
At Drive My Way, they create the best job match possible for CDL truck drivers and employers. Their unique, online, personalized recruiting service has significant benefits for both sides. If you’re a driver, Drive My Way matches you to the job that best fits your qualifications and preferences, so you can achieve the lifestyle you want. Do youdesire more home time and better benefits? Select those preferences and their one-of-a-kind Match My Way technology will filter the job results to make it happen.For employers, Drive My Way facilitates the best job match possible, so you can be confident you have hired the right driver for the position. With the Match My Way score their technology generates, employers can know exactly how well a candidate meets a job’s requirements before entering into the hiring process.That means finding the right candidate is done efficiently, which will lower recruiting costs and decrease turnover for you. | $4.4M / Series A / Sep 29, 2022 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does JobsOhio Growth Capital Fund invest in?
JobsOhio Growth Capital Fund invests primarily in Health Care, Information Technology and Medical startups, most often at Series A and Series C stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did JobsOhio Growth Capital Fund last invest?
The most recent investment recorded for JobsOhio Growth Capital Fund closed in Feb 2024. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
